Colin J. H. Brenan
Colin J.H. Brenan is a serial life sciences entrepreneur with over 30 years experience in scientific research, project management, product development, strategic marketing and financing of early-stage life science companies. He is presently Chief Technology Officer and Head of Business Development for his most recent venture HiFiBiO BV. Colin received his B.Sc. (Honours Physics), M.Eng. (Electrical) and Ph.D. (Biomedical Engineering) from McGill University (Montreal, Canada) and completed post-doctoral training at MIT (Cambridge, USA).
A critical and often underappreciated step in the development of a new small-molecule drug is its manufacture into a pill for oral delivery. It is critical to maintain the biochemical potency that makes the drug a desirable therapeutic while simultaneously building in the physicochemical properties needed to meet the pharmacokinetic profile required for optimal clinical results
Junjiu Huang, a researcher at Sun Yat-Sen University in Guangzhou, reported recently on his team’s attempt to edit mutations with the CRISPR/Cas9 system
Since taking the helm of IEEE Pulse in January 2014, I am very proud of how we have built on the solid journalistic foundation constructed by former Editor-in-Chief Mike Neuman to broaden the scope, increase the visibility, and heighten the global impact of the magazine
The advent of oncology therapies acting against molecular targets in pathways inhibiting carcinogenesis has opened new treatment options with greatly reduced toxicities. A recent example is the blocking of the epidermal growth factor signaling pathway by the binding of a monoclonal antibody to the EGF receptor or the inhibition of tyrosine kinase activity in the EGF pathway
In our January article on hot trends in biomedical engineering for 2014, we predicted the CRISPR/Cas system to become a transformative and powerful tool for gene editing. The simplicity, precision, speed, and low cost by which one or more gene sequences can be selectively silenced, enhanced or changed with CRISPR
Recently, I was sitting in a local coffee shop trying to think of a topic for my editorial in this issue of IEEE Pulse, and I was having little success. I thought it ironic that I spend the majority of my day writing e-mails, proposals, and reports but couldn’t think of a topic for what should be a simple assignment: writing this column. Since becoming editor-in-chief of IEEE Pulse, I am now challenged to think of interesting topics on which I can opine on a regular basis. After some thought, I elected to fall back on the tried and true writer’s adage and write about what I know: what it is like to be a serial entrepreneur.
Beginning in January 2014, Colin Brenan succeeds Mike Neuman as editor-in-chief (EIC) of IEEE Pulse, and on his agenda are a number of editorial changes designed to increase the magazine’s accessibility and broaden its appeal to a global biomedical engineering audience